×
About 708 results
VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

CYRAMZA® (ramucirumab)
http://www.cyramzahcp.com/

CYRAMZA, combined with other medications, is used for the treatment of patients with advanced gastric cancer or GEJ, metastatic non-small cell lung cancer (NSCLC), and metastatic colorectal cancer (mCRC).

LORBRENA® (Lorlatinib)
https://www.lorbrenahcp.com/

LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on

FoundationOne CDx - Foundation Medicine
https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx

FoundationOne CDx is the first FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors

PORTRAZZA (necitumumab) injection
https://www.lillymedical.com/us/en/oncology/portrazza/index.aspx

PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

OPDIVO (nivolumab) injection
http://www.opdivohcp.com/

Learn more about OPDIVO® (nivolumab). Prescribed medication to treat certain types of cancers. Read about its indications, clinical data and efficacy.

GILOTRIF® (afatinib) TABLETS
https://www.gilotrifhcp.com/

Learn more about GILOTRIF (afatinib) tablets, a treatment for patients with Del 19 or L858R EGFR mutation-positive mNSCLC, or patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy. View Important Safety Information and Prescribing Information including Patient Information.

IMFINZI® (durvalumab) INJECTION
https://www.imfinzi.com/hcp.html

Request A Representative To Help Answer Your Questions About IMFINZI.

INFUGEM™ - Gemcitabine In Sodium Chloride‎
http://infugem.com/

For US Healthcare Professionals. View Indications, Usage & Full Prescribing Information

PORTRAZZA™ (necitumumab) injection
http://www.portrazza.com/hcp/

PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Gemzar® (gemcitabine for injection)
http://pi.lilly.com/us/gemzar.pdf

Gemzar. GEMZAR (gemcitabine for injection), for intravenous use. Initial U.S. Approval: 1996 ..... http://www.osha.gov/SLTC/hazardousdrugs/index.html. 2.7.

IRESSA (gefitinib) TABLETS
https://www.iressa-usahcp.com/

IRESSA is a treatment for patients with metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension)
https://www.abraxanepro.com/

Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.

ALECENSA® (alectinib)
http://alecensa.com/hcp.html

Find information for healthcare professionals about ALK+ metastatic non-small cell lung cancer treatment with ALECENSA® (alectinib). Important Safety Information. Hepatotoxicity: Monitor liver function tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more ...

ALIMTA® (pemetrexed)
https://www.alimta.com/hcp/

Find efficacy and safety data for ALIMTA in advanced nonsquamous NSCLC and malignant pleural mesothelioma, plus videos and resources for your patients.

AVASTIN® (bevacizumab)
https://www.avastin-hcp.com/

Learn about Avastin® (bevacizumab) for FDA approved indications. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (rOC) Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial

CHANTIX® TABLETS (varenicline)
https://www1.pfizerpro.com/product/chantix/hcp

CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX. Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have been reported in patients treated with CHANTIX. These included changes in mood (including depression and mania)

TAFINLAR® (dabrafenib) CAPSULES + MEKINIST® (trametinib) TABLETS
https://www.hcp.novartis.com/products/tafinlar-mekinist/

TAFINLAR® (dabrafenib) capsules, in combination with MEKINIST® (trametinib) tablets, is indicated for the treatment of patients with: ... Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ... MEKINIST is not indicated for the ...

Tarceva® (erlotinib) mNSCLC & Pancreatic Cancer Treatment
https://www.tarceva.com/hcp/

First-line treatment for EGFR mutation-positive metastatic NSCLC with exon 19 deletions or exon 21 (L858R) substitution mutations

Zykadia® (ceritinib)
https://www.hcp.novartis.com/products/zykadia/alk-nsclc/

As a healthcare professional (HCP), learn more about ZYKADIA. ... cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as ...